Background: Deoxyribonucleoside triphosphates (dNTPs) are the building blocks of DNA and are essential for cancer cell growth and survival. Ribonucleotide reductase (RNR) regulates a rate-limiting step in the supply of dNTP, which suggests RNR as a promising therapeutic target of cancer. TAS1553 is a novel class of RNR inhibitor that abrogates protein-protein interactions between RNR subunits; this compound has shown promising antitumor activity in preclinical models for both solid tumors and hematological malignancies.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2020 Elsevier B.V. Published by Elsevier Inc. All rights reserved.